RxDoctor Payments Data

Jessica Whitlock

Family · Saint Louis, MONPI 1295107506

Payments from drug & device makers

$4,937in general payments, 2019–2025

Across 80 payments — averaging $61.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$933
  • AstraZeneca$750
  • Lilly USA, LLC$426
  • GSK$338
  • Novo Nordisk$266
  • Edwards Lifesciences$244
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,936100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,937 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$40,484
Medicare patients
239
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$15,066
EliquisApixaban11$11,876
Doxycycline Hyclate73$638
Methylprednisolone99$637
Ofloxacin16$462
Albuterol Sulfate HfaAlbuterol Sulfate30$451
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav51$416
Buspirone Hcl19$369
Cefdinir18$367
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst27$340
Cyclobenzaprine Hcl33$322
Omeprazole26$319
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$287
Sertraline Hcl31$247
Losartan Potassium30$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$266$15,06611 claims
PfizerEliquis$81$11,87611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →